Cynvenio Biosystems, Inc. To Present New Clinical Data On Concordance Characteristics Of Circulating Cell-Free Nucleic Acids In Metastatic Cancer Mutations At Molecular Diagnostics Europe

Unique study sequences matched CTC, cfDNA and FFPE sample sets;
Third annual event will be held April 13-16 in Lisbon, Portugal

LOS ANGELES--(BUSINESS WIRE)--Cynvenio Biosystems, Inc., the only molecular information technology company that can analyze both cell free DNA (cfDNA) and circulating tumor cells (CTC) from the same blood sample, will present recent findings that establish that both ctcDNA and cfDNA can be used as informative and complementary data types for the analysis of tumor-associated mutations by next generation sequencing (NGS) at this month’s third international Molecular Diagnostics Europe event in Lisbon, Portugal.

“The molecular analysis of ctcDNA and cfDNA requires robust enrichment and analytical technology to overcome both limiting template and very high signal to noise ratios. Our methodology derives complementary information from the same blood specimen, and the two templates should be jointly analyzed to fully characterize any given cancer”

The abstract, entitled “LiquidBiopsy: A Molecular Platform to Support Next Generation Sequence Analysis of Circulating Tumor Cells and Circulating Tumor DNA,” will be presented by Cynvenio Chief Scientific Officer Paul Dempsey, Ph.D., as part of the inaugural Circulating Cell-Free Nucleic Acids track on Thursday, April 16, at 3:50 p.m.

This interim dataset was developed as part of an ongoing 60 patient, NCI-funded study to analyze tumor cell populations from blood and tissue (FFPE) in collaboration with researchers at Thomas Jefferson University Cancer Center (Philadelphia), Emory University (Atlanta) and the West Clinic (Memphis, Tennessee).

“The molecular analysis of ctcDNA and cfDNA requires robust enrichment and analytical technology to overcome both limiting template and very high signal to noise ratios. Our methodology derives complementary information from the same blood specimen, and the two templates should be jointly analyzed to fully characterize any given cancer,” notes Dempsey. “We know that cfDNA, or DNA fragments in the bloodstream, are produced in varying levels depending on the size of the tumor. It has also been previously established that CTCs, or whole tumor cells, relate to the aggressiveness of disease in that they have been shown to drive metastatic events.”

During the abstract presentation new data will be shared describing how Cynvenio’s LiquidBiopsy instrumentation platform, a turnkey system for academic and pharma R&D programs in oncology, supports NGS analysis of ctcDNA and cfDNA from a single blood sample by pairing novel enrichment technology with high sensitivity sequencing in an Ion Torrent™ PGM™ run.

In addition to the Circulating Cell-Free Nucleic Acids track, the event will feature three related tracks on the new era in medicine: Prenatal Molecular Diagnostics, Cancer Sequencing and Advanced Diagnostics for Infectious Disease – representing the hottest areas for applying molecular diagnostics to the clinical setting. For more information, visit www.moleculardxeurope.com.

Presentation Details:

Time and Date: Thursday, April 16, 2015, 3:50 p.m.

Title: LiquidBiopsy: A Molecular Platform to Support Next Generation Sequence Analysis of Circulating Tumor Cells and Circulating Tumor DNA

Track: Circulating Cell-Free Nucleic Acids

Type: Session, sponsored by Thermo Fisher Scientific

Location: Marriott Hotel, Lisbon, Portugal

Presenter: Paul W. Dempsey Ph.D., Chief Science Officer, Cynvenio Biosystems Inc.

About Cynvenio Biosystems, Inc.

Cynvenio is a molecular information technology company that helps make individualized cancer treatment possible by providing longitudinal insights into each patient via the genomic analysis of their cancer from a standard blood draw.

Cynvenio’s LiquidBiopsy® clinical assays for solid tumors are used as therapy finders to periodically assess patients’ individual mutations and match them with targeted cancer therapies and clinical trials. The company’s tests complement traditional tissue biopsy analysis or can be used as standalone tests when tissue biopsy is deemed difficult or too risky to collect.

Cynvenio is headquartered in Westlake Village, California (Los Angeles). For more information, visit http://www.cynvenio.com.

LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.
Ion Torrent and PGM are trademarks of Life Technologies and Thermo Fisher Scientific.